No abstract available.
Humans ; Immunity, Humoral* ; Sputum*

To evaulate the possible pathogenetic significance of allergen-specific IgA antibody in respiratory secretion from asthmatics, we measured house dust mite(HDM)-specific IgA antibody in 3% saline-induced sputum from 23 HDM-sensitive asthmatics, 4 atopic asthmatics without mite-sensitivity, 6 non-atopic asthmatics, and 13 non-atopic, non-asthmatic controls (including 6 non-atopic healthy controls, 4 patients with chronic bronchitis, and 3 patients with rheumatoid arthritis) by ELISA. We also measured HDM-specific IgA antibody in serum and numbers of eosinophils in sputum. 1) Levels of HDM-specific IgA antibody in sputum from mite-sensitive asthmatics were significantly higher than those from non-atopic, non-asthmatic controls and non-atopic asthmatics(p<0.05). Levels of HDM-specific IgA antibody in sputum from atopic asthmatics without mite-sensitivity were significantly higher than those from non-atopic, non-asthmatic controls (p<0.05), however HDM-specific IgA/albumin raito was not significantly different between two groups (p>0.05). 2) The ratio of HDM-specific IgA antibody to albumin in sputum was not significantly different in mite-sensitive asthmatics with sputum eosinophila (> or = 5% of 200 counted leukocytes) and those without sputum eosinophilia (p>0.05). 3) The ratio of HDM-specific IgA to albumin in sputum from asthmatics was higher than that of serum. 4) There was no significant correlation of HDM-specific IgA/albumin ratios between serum and sputum (p>0.05). 5) When comparing sputum and saliva samples from 7 mite-sensitive asthmatics, levels of HDM-specific IgA antibody in sputum were significantly higher than those in saliva (p<0.05). In conclusion, HDM-specific IgA anti-body was increased in sputum from HDM-sensitive asthmatics, and it might be locally produced from bronchial mucosa. To evlauate the pathogenetic significance of allergen-specific IgA antibody in respiratory secretion from asthmatics, further studies might be needed.
Bronchitis, Chronic ; Dust* ; Enzyme-Linked Immunosorbent Assay ; Eosinophilia ; Eosinophils ; Humans ; Immunoglobulin A* ; Mucous Membrane ; Saliva ; Sputum*

BACKGROUND: Measurement of allergen-specific IgE antibodies using enzyme-linked immunosorbent assay (ELISA) has been developed and the results were shown to correlate well with those obtained by radioimmunoassay (RIA). However, consensus on the optirnal condition and data expression method for the measurement of allergen-specific IgE using ELISA is still not present. Object: To define the optimal condition for the measurement of allergen-specific IgE using ELISA and to evaluate the accuracy and reproducibility of the results, METHOD: We measured the concentrations of house dust mite-specific IgE antibodies in serum samples by ELISA and RIA method (AlaSTAT, DPC, USA) using standardized Dermatop~hagoides farinae antigen (kindly donated by Allergopharma Joachim Ganzer KG, Reinbek, Germany). RESULTS: Optirnal antigen coating amount was 2 ug/well and optimal serum dilution was 1: 10 for ELISA. The expression of the absolute concentration of house dust mite-specific IgE antibodies within the unknown sample using serial dilutions of samples and standard serum seemed to be more reasonable than the expression of absorbance value at a single serum dilution, because the former method provided better inter-assay variation and correlation with RIA results. The results of specific IgE rneasurement using ELISA significantly correlated with RIA results (r=0.96, p<0.001, n=26). CONCLUSION: These findings suggest that the measurement of allergen-specific IgE antibodies using the ELISA method can be accurate and reliable if optimal assay conditions and standardized data expression are applied.
Antibodies* ; Consensus ; Dust* ; Enzyme-Linked Immunosorbent Assay* ; Immunoglobulin E* ; Pyroglyphidae ; Radioimmunoassay

BACKGROUND: Toluene diisocyanate (TDI) is the most prevalent agent to cause occupational asthma (OA) in Korea. The pathogenic mechanism of TDI-induced OA is still unclear. Involvement of both immunological and non-immunologicaI mechanisms have been suggested. OBJECTIVE: To evaluate a possible role of neutrophil in the development of TDI-asthma. OBJECT AND METHOD: Myeloperoxidase (MPO) as a neutrophil activation marker in both serum and induced sputum, and IL-8 in induced sputum were measured. Induced sputa and sera were collected from 15 TDI-induced OA patients (classified to group I) during TDI- bronchoprovocation test and were compared with those from 11 asthmatic subjects with negative TDI-bronchoprovocation test (group II). MPO levels were measured by radioimmunoassay, IL-8 levels, by enzyme linked immunosorbent assay and albumin levels, by nephelometry. Sputum MPO and IL-8 levels were presented as a ratio to albumin. RESULT: Serum MPO level tended to decrease during the TDI-bronchoprovocation test in two groups, but no statistical significance was reached (p>0.05). However, the ratios of MPO (the ratio of MPO level measured at 30 min to MPO level at baseline, and the ratio MPO level measured at 360 min to MPO baseline) in group I were significantly lower than group II (p=0.004, p=0.03 respectively). The IL-8/albumin and MPO/albumin levels in induced sputum from group I were significantly increased after the TDI-bronchprovocation test in comparison to the baseline value which was obtained before the bronchoprovocation test (p=0.0l, p=0.02 respectively). There was a significant correlation between the percent increase of IL-8/albumin and the MPO/albumin in induced sputum (r=0.89, p<0.05). CONCLUSION: These findings suggest a possible involvement of neutrophil in the development of bronchoconstiction after the TDI exposure, and IL-8 might contribute to neutrophil recruitment to airway mucosa. Further investigation will be needed to investigate mechanism of neutrophil activation in the pathogenesis af TDI-induced OA.
Asthma, Occupational* ; Enzyme-Linked Immunosorbent Assay ; Humans ; Interleukin-8 ; Korea ; Mucous Membrane ; Nephelometry and Turbidimetry ; Neutrophil Activation* ; Neutrophil Infiltration ; Neutrophils* ; Peroxidase ; Radioimmunoassay ; Sputum* ; Toluene 2,4-Diisocyanate

OBJECTIVE: In order to confirm the local production of total and specific IgE antibodies in the nasal polyp tissues. MATERIAL AND METHOD: We measured total IgE and house dust mite(Dermatophagoides pteronpssinus .' DP)-specific IgE antibody using enzyme-linked immunosorbent assay(ELISA) in the supernatant of nasal polyp homogenates from 72 subjects undergoing nasal polypectomy. The subjects were divided into three groups according to skin reactivity to DP: 20 strongly atopic subjects to group I(mean wheal diameter) 3mm), 19 weakly atopic subjects to group II (mean wheal diameter 1-3mm) and 33 negative skin responders to group III. RESULT: Group I showed significantly higher levels of total and DP-specific IgE levels in the nasa
Antibodies ; Dust* ; Immunoglobulin E* ; Nasal Polyps* ; Pyroglyphidae* ; Skin ; United States National Aeronautics and Space Administration

Isocyanate is the most prevalent agent in occupational asthma(OA) in Korea. We analyzed 43 toluene diisocyanate(TDI) induced OA patients of whom 81% were found to be spray painters. The bronchial sensitivity of all subjects was confirmed by TDI-bronchial challenge test. Serum-specific IgE antibodies to isocyanate-human serum albumin(HSA) conjugate were detected by RAST technique(Pharmacia, Sweden). Bronchial challenge test results revealed 21(57%) early, 5 late only, 4 dual, and 12 atypical responders(5 prolonged immediate, 6 square-shaped, 1 progressive). Four(9%) subjects had negative results on the methacholine bronchial challenge test. High levels of serum specific IgE antibody to isocyanate-HSA were found in 17(40%) patients. The prevalence of a specific IgE antibody was not associated with a type of TDI-bronchial challenge test response, smoking and atopic status, presence of rhino-sinusitis and systemic symptoms, or a degree of airway hyperresponsiveness to methacholine(p> 0.05). The period of latency, ranging from 3 to 132 months, was significantly longer in high specific IgE responders (p< 0.05). These data suggest that 40% of isocyanate-induced occupational asthma patients had high specific IgE antibody to isocyanate-HSA conjugate. The presence of specific IgE antibody does not seem to correlate with clinical parameters.
Allergens/adverse effects/*immunology ; Asthma/chemically induced/*immunology ; Female ; Human ; Immunoglobulin E/blood/*immunology ; Male ; Occupational Exposure/*adverse effects ; Toluene 2,4-Diisocyanate/adverse effects/*immunology

The current standard medical therapy for atopic dermatitis (AD) mainly focuses on symptomatic relief by controlling skin inflammation with topical corticosteroids and/or topical calcineurin inhibitors. However, the clinical efficacy of pharmacological therapy is often disappointing to both patients and physicians. The terminology of AD contains a historical meaning of eczematous dermatitis caused by hypersensitivity reaction to environmental inhalant or food allergen. Complex interrelationships among genetic abnormalities, environmental triggers, skin barrier defects, and immune dysfunction resulting in a vicious domino-circle seem to be involved in the development and maintenance of AD. In the viewpoint of AD as an allergic disease, complete avoidance of clinically relevant allergen or induction of specific immune tolerance through administrations of allergen (allergen immunotherapy) can provide clinical remission by breaking the vicious domino-circle maintaining a chronic disease state. In recent clinical studies, monoclonal antibodies including the anti-interleukin-4 receptor antibody and anti-B cell antibody induced significant clinical improvements in patients with AD. The detailed characteristics of immune dysfunction are heterogeneous among patients with AD. Therefore, a personalized combination of immunomodulatory therapies to reduce hypersensitivity (allergen immunotherapy) and correct immune dysfunction (monoclonal antibody therapy) could be a reasonable therapeutic approach for patients with AD. Future immunomodulatory therapies for AD should be developed to achieve long-term treatment-free clinical remission by induction of immune tolerance.
Adrenal Cortex Hormones ; Allergens ; Antibodies, Monoclonal ; Calcineurin ; Chronic Disease ; Dermatitis, Atopic* ; Eczema ; Humans ; Hypersensitivity ; Immune Tolerance ; Immunomodulation* ; Inflammation ; Skin

Background and OBJECTIVE: There has been a few case reports of anaphylaxis due to honeybee in Korea. In order to observe the clinical feature of bee sting anaphylaxis. Moderials and methods: Six patients living in Kyunggi province area were referred under history of anaphylaxis after the bee sting. Atopy was defined by skin prick test result to common inhalant allergen. Serum specific IgE antibody to each bee antigen was detected by radioimmunoassay to identify the causative bee. RESULTS: All six cases were female. Three had atopy and four had combined allergic diseases such as allergic rhinitis, asthma, and urticaria. The etiologic bees consisted of yellow jacket (6 cases), paper wasp (4 cases), yellow hornet (3 cases), white faced hornet (1 case) and honey bee (1 case). Four cases had experienced anaphylaxis after ant bite and they showed positive result on specific IgE to imported fire ant. Specific immunotherapy against causative bee venom was begun using bee venom extracts from Bayer (USA) based upon results of specific IgE anti-body to bee venom. CONCLUSION: The yellow jacket is the most common cause of bee venom anaphylaxis in this area. Further studies will be needed to evaluate possible cross-reactivity between bee and ant venom.
Anaphylaxis* ; Ant Venoms ; Ants ; Asthma ; Bee Venoms* ; Bees* ; Bites and Stings ; Female ; Fires ; Gyeonggi-do ; Honey ; Humans ; Immunoglobulin E ; Immunotherapy ; Korea ; Radioimmunoassay ; Rhinitis ; Skin ; Urticaria ; Wasps

Aspirin(ASA) and NSAIDs can induce bronchoconstriction in 10~20% of adult asthmatics patients. Inhalation of lysine-ASA(L-ASA) has been described as an alternative method for diagnosis of ASA-sensitive asthma. To further understand the characterlstics of ASA-sensitive asthmas. we studied 38 asthmatic patients with ASA -sensitivity (36 intrinsic and 2 extrinsic asthma) proven by L-ASA bronchoprovocation test (BPT). Most were female (male to female ratio was 27:73). Twenty (53%) of them had no previous history of adverse reactions when exposed to ASA. Twenty nine (79%) had rhino-sinusitis symptoms. Early asthmatic response was observed in 16 (42%) patients, late only response in 16(42%), and dual response in 6(16%) patients. The threshold of L-ASA to provoke a positive response ranged from 11.2 to 180 mg/ml and most (68.3%) had a positive response after the inhalation of 180 mg/ml. Concurrent sensitivity to sulfite was noted in 14 (36%) patients, followed by sensitivity to tartrazine in one (3%) patient. None showed a positive response to sodium benzoate. After the avoidance from ASA/ NSAIDs with administration of anti-asthmatic medications, symptom and medication scores reduced in 26(87%) patients among 30 followed patients. They were classified into the improved group: four (13%) patients belonged to the not-improved group. There were no significant differences in clinical characteristics between the improved and not- improved group (p>0.05). In conclusion, L-ASA BPT could be considered as a useful method to diagnose ASA -sensitive asthma and be used to screen the causative agent for asthmatic patients with intrinsic type, especially in female patients with rhino-sinusitis and/or nasal polyp, even though they do not have arty history of adverse reactions. Cessation of exposure and proper treatment may allow to reduce symptom and medication scores.
Adult ; Anti-Inflammatory Agents, Non-Steroidal ; Asthma* ; Bronchoconstriction ; Diagnosis ; Female ; Humans ; Inhalation ; Nasal Polyps ; Sodium Benzoate ; Tartrazine

Current pharmacological therapies for allergic diseases can improve clinical symptoms but cannot change their long-term clinical course. There is an unmet need for a curative treatment for allergic diseases. Allergen immunotherapy (AIT) is the practice of administering increasing doses of clinically relevant allergens to an allergic subject to reduce the clinical symptoms associated with subsequent exposure to the allergen. AIT is clinically effective for allergic asthma, allergic rhinitis, venom-induced anaphylaxis, and atopic dermatitis. AIT can change the natural course of allergic diseases and induce allergen-specific immune tolerance. In current clinical practice, AIT is delivered either subcutaneously or sublingually. Both subcutaneous and sublingual AIT have long-term therapeutic efficacy after of 3-5 years of treatment. The development of safer and more effective AIT strategies is needed. Conclusion: AIT is a disease-modifying therapy for allergic diseases. Future development of AIT should be directed toward achieving long-term clinical remission in patients with allergic diseases by the safe and effective induction of immune tolerance.
Allergens ; Anaphylaxis ; Asthma ; Dermatitis, Atopic ; Desensitization, Immunologic* ; Humans ; Hypersensitivity ; Immune Tolerance ; Immunomodulation ; Immunotherapy ; Rhinitis